WO1989005146A3 - Methode de traitement de la dyslipidemie chez les etres humains - Google Patents

Methode de traitement de la dyslipidemie chez les etres humains Download PDF

Info

Publication number
WO1989005146A3
WO1989005146A3 PCT/US1988/004199 US8804199W WO8905146A3 WO 1989005146 A3 WO1989005146 A3 WO 1989005146A3 US 8804199 W US8804199 W US 8804199W WO 8905146 A3 WO8905146 A3 WO 8905146A3
Authority
WO
WIPO (PCT)
Prior art keywords
dyslipidemia
humans
salicylamide
phenylpropyl
treatment
Prior art date
Application number
PCT/US1988/004199
Other languages
English (en)
Other versions
WO1989005146A2 (fr
Inventor
William Darrow
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to KR1019890701418A priority Critical patent/KR890701111A/ko
Publication of WO1989005146A2 publication Critical patent/WO1989005146A2/fr
Publication of WO1989005146A3 publication Critical patent/WO1989005146A3/fr
Priority to DK132090A priority patent/DK132090D0/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

Methode de traitement de la dyslipidémie chez un être humain, en particulier lorsque la dyslipidémie se caractérise par un niveau de cholestérol du sérum HDL inférieur à 50 mg par décilitre. La méthode consiste à administrer à l'être humain une quantité thérapeutiquement efficace de 5-{(R)-1-hydroxy-2-[(R)-(1-méthyle-3-phénylpropyle)amino]-éthyle}salicylamide, 5-{(S)-1-hydroxy-2-[(R)-(1-méthyle-3-phénylpropyle)amino]éthyle}salicylamide ou un sel ou un mélange pharmaceutiquement acceptable de ces composés.
PCT/US1988/004199 1987-11-30 1988-11-28 Methode de traitement de la dyslipidemie chez les etres humains WO1989005146A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019890701418A KR890701111A (ko) 1987-11-30 1988-11-28 사람의 이상지혈증의 치료방법
DK132090A DK132090D0 (da) 1987-11-30 1990-05-29 Fremgangsmaade til behandling af dyslipidaemi hos mennesker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/126,441 US4788183A (en) 1987-11-30 1987-11-30 Method for treatment of dyslipidemia in humans

Publications (2)

Publication Number Publication Date
WO1989005146A2 WO1989005146A2 (fr) 1989-06-15
WO1989005146A3 true WO1989005146A3 (fr) 1989-10-19

Family

ID=22424849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/004199 WO1989005146A2 (fr) 1987-11-30 1988-11-28 Methode de traitement de la dyslipidemie chez les etres humains

Country Status (10)

Country Link
US (1) US4788183A (fr)
EP (2) EP0391958A1 (fr)
JP (1) JPH02503314A (fr)
KR (1) KR890701111A (fr)
AU (1) AU2816889A (fr)
DK (1) DK132090D0 (fr)
HU (1) HUT53526A (fr)
NZ (1) NZ227123A (fr)
WO (1) WO1989005146A2 (fr)
ZA (1) ZA888993B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
US6264960B1 (en) 1998-11-10 2001-07-24 Sander J. Robins Treatment of vascular events using lipid-modifying compositions
US20040072903A1 (en) * 2001-05-08 2004-04-15 Auerbach Bruce Jeffrey Carboxyalkylether-acat inhibitors combinations
US20060057231A1 (en) * 2004-08-19 2006-03-16 Rimando Agnes M Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
ZA794872B (en) * 1978-09-20 1980-11-26 Schering Corp A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Advances in Therapy, volume 1, no. 5, September 1984, Health Communications Inc., (Milwaukee, WI, US), M.S. Kochar et al.: "Effect of beta blockers and converting enzyme inhibitors on serum lipids", pages 370-375 *
Br. J. Pharmac., volume 77, 1982, The Macmillan Presws Ltd, R.T. Brittain et al.: "The x- and B-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues", pages 105-114 *
Chemical Abstracts, volume 104, no. 25, 23 June 1986, (Columbus, Ohio, US), K. Matsunaga et al.: "Alpha- and B-adrenoceptor blocking activities of dilevalol, R, R-isomer of labetalol, in isolated guinea pig tissues", see pages 35-36 *
Chemical Abstracts, volume 96, no. 23, 7 June 1982, (Columbus, Ohio, US), J..E. Clifton et al.: "Arylethanolamines derived from salicylamide with x- and B-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers and related salicylamides", see page 628 *
Chemical Abstracts, volume 97, no. 19, 8 November 1982, (Columbus, Ohio, US), E.H. Gold et al.:, "Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol", see page 672 *
J. Clin. Hypertens, volume 3, no. 3, September 1987, Elsevier Science Publishing Co., Inc., (New York, US), E. Saunders et al.: "Labetalol compared with propranolol in the treatment of black hypertensive patients", pages 294-302 *
J. Clin. Pharmacol. volume 24, 1984, M.A. Weber et al.: "The combined alpha- and beta-adrenergic blocker labetalol and propranolol in the teatment of high blood pressure: similarities and differences", pages 103-112 *
J. Med. Chem., volume 25, 1982, American Chemical Society, E.H. Gold et al.: "Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol", pages 1363-1370 *
Journal of Cardiovascular Pharmacology, volume 11, suppl. 2, 1988, Raven Press, Ltd, (New York, US), B.J. Materson et al.: "Dilevalol compared to metoprolol for treatment of hypertension: a multicenter trial", page S37 *
Journal of Cardiovascular Pharmacology, volume 11, suppl. 2, 1988, Raven Press, Ltd, (New York, US), W.J. Louis et al.: "Actions of Dilevalol on adrenoceptors", pages S5-S11 *
Klinische Wochenschrift, volume 62, no. 18, 1984, Springer-Verlag, B.G. Woodcock et al.: "Beta-blocker induced changes in the cholesterol: high-desity lipoprotein cholesterol ratio and risk of coronary heart disease", pages 843-849 *
S. Afr. Med. J., volume 60, no. 10, 1981, De K. Sommers et al.: "The effects of labetalol and oxprenolol on blood lipids", pages 379-380 *

Also Published As

Publication number Publication date
DK132090A (da) 1990-05-29
EP0391958A1 (fr) 1990-10-17
AU2816889A (en) 1989-07-05
HU890492D0 (en) 1990-09-28
WO1989005146A2 (fr) 1989-06-15
KR890701111A (ko) 1989-12-19
JPH02503314A (ja) 1990-10-11
US4788183A (en) 1988-11-29
JPH0532368B2 (fr) 1993-05-14
ZA888993B (en) 1989-07-26
HUT53526A (en) 1990-11-28
EP0318889A3 (fr) 1989-11-29
EP0318889A2 (fr) 1989-06-07
DK132090D0 (da) 1990-05-29
NZ227123A (en) 1990-08-28

Similar Documents

Publication Publication Date Title
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
FI935847A0 (fi) L-DOPA-esterkompositioner
BR9609063A (pt) Dinucleotídeos úteis para o tratamento de doenças pulmonares
CA2255652A1 (fr) Isobutylgaba et ses derives utilises pour le traitement de la douleur
CA2070281A1 (fr) Traitement ameliore des maladies auto-immunes par administration aerosol d'auto-antigenes
WO1993021894A3 (fr) Traitement de la degenerescence maculaire
AU1331588A (en) Method for treatment of alcohol abuse
CA2190303A1 (fr) Composition pharmaceutique; methode et dispositif pour prevenir ou traiter le syndrome sec ou les maladies qui en decoulent
CA2139385A1 (fr) Produits renfermant une proteine liante de g-csf et de tnf
EP0376899A3 (fr) Utilisation des dérivés de la L-carnitine pour la fabrication d'un médicament pour le traitement thérapeutique des neuropathies pêriphériques
DK562488D0 (da) Farmaceutisk praeparat indeholdende polyminderivater, samt nogle af disse polyaminderivater
WO1989005146A3 (fr) Methode de traitement de la dyslipidemie chez les etres humains
EP0361888A3 (fr) Dérivés de l'acide apovincaminique
WO1996005836A3 (fr) Procedes de traitement de symptomes dus au froid au moyen de la pentoxifylline
EP0354568A3 (fr) Dérivés du catéchol
IE870577L (en) Topical amide preparation
CA2190952A1 (fr) Inhibition des infections retrovirales par administration de composes de l'acide naphtalene sulfonique
BG60164A3 (en) Method for preparing of stereoisomers
NO178622C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive kynurensyrederivater, samt mellomprodukter egnet for fremstilling derav
IE840198L (en) Therapeutic use of nafazatrom
IE900303L (en) 18-cyanoprogesterone derivatives
EP0142756A3 (fr) Dérivés de méthyl-pipérazine avec une activité analgésique, procédé pour leur préparation et composés thérapeutiques les contenant
MY110416A (en) Composition for the treatment of schizophrenia.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR DK FI HU JP KP KR LK MC MG MW NO RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR DK FI HU JP KP KR LK MC MG MW NO RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1989900733

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989900733

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989900733

Country of ref document: EP